This Review assesses the mechanism-based biomarkers in use and in development for immune checkpoint inhibition, identifying cancer types and cancer phenotypes that are most likely to respond to immune checkpoint blockade, and considerations for future biomarkers of immune checkpoint response.
- Suzanne L. Topalian
- Janis M. Taube
- Drew M. Pardoll
